Form 4: CVS Health Executive Amy Compton-Phillips Awarded Significant Equity Compensation

CVS Health's EVP and Chief Medical Officer, Amy Compton-Phillips, has been granted 53,091 restricted stock units and 27,081 stock options, aligning her incentives with shareholder value.

Summary

• Amy Compton-Phillips, EVP and Chief Medical Officer of CVS Health Corp (CVS), was awarded 53,091 Restricted Stock Units (RSUs) on May 31, 2025.
• The RSUs were granted at a price of $64.04 per share.
• A portion of the RSUs (46,845 units) will vest in three equal annual installments, commencing May 31, 2026.
• The remaining RSUs (6,246 units) will vest in four equal annual installments, also commencing May 31, 2026.
• Additionally, Ms. Compton-Phillips was granted 27,081 stock options with an exercise price of $64.04.
• These stock options become exercisable in four equal annual installments, commencing May 31, 2026, and expire on May 31, 2035.
• All awards were made pursuant to the Issuer's 2017 Incentive Compensation Plan.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates a standard and beneficial executive compensation event, aligning management's interests with shareholders through equity awards. It reflects stability in leadership and a commitment to long-term performance.

Positives

• The significant equity awards align the executive's financial interests directly with the long-term performance and shareholder value of CVS Health.
• The grants serve as a strong retention mechanism for a key executive, the EVP and Chief Medical Officer.
• The use of a Rule 10b5-1(c) plan indicates a pre-planned and transparent approach to executive compensation.

Future Outlook

The document details future vesting schedules for the awarded equity, with the first installments commencing on May 31, 2026, and stock options expiring on May 31, 2035, indicating a long-term incentive structure.

Industry Context

This filing reflects standard executive compensation practices within the healthcare and pharmacy benefits management industry, where equity awards are commonly used to incentivize and retain senior leadership. CVS Health, as a major integrated healthcare provider, utilizes such compensation to align its executives with long-term strategic goals in a competitive sector.

Related Party Transactions

• The transaction involves the grant of equity awards from CVS Health Corp to its EVP, Chief Medical Officer, Amy Compton-Phillips, which is a standard related-party compensation arrangement.

Stakeholder Impact

• Shareholders: The equity awards align the executive's interests with shareholder value, potentially leading to better long-term performance.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.
• Executive (Amy Compton-Phillips): Receives significant long-term incentive compensation, enhancing personal wealth tied to company performance.

Next Steps

• Vesting of 46,845 RSUs in three equal annual installments, commencing May 31, 2026.
• Vesting of 6,246 RSUs in four equal annual installments, commencing May 31, 2026.
• Stock options becoming exercisable in four equal annual installments, commencing May 31, 2026.

Key Dates

Keywords

CVS Health, CVS, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Equity Award, Corporate Governance, Amy Compton-Phillips, Chief Medical Officer